Abstract: A thermally activated delayed fluorescence green light polymer material and an organic electroluminescent device thereof are provided. The thermally activated delayed fluorescence green light polymer material is based on a boron-containing structure, an overall charge transfer strength is adjusted through different electron donor units, so as to synthesize a series of green light thermally activated delayed fluorescence materials with low single-triplet energy level differences, high luminous efficiency, and fast reverse intersystem crossing constants, while realizing the fine-tuning of the electron-donor ability of the electronic donor unit to make the spectrum fine-tune.
Type:
Grant
Filed:
April 3, 2020
Date of Patent:
January 23, 2024
Assignee:
WUHAN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD.
Abstract: The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
Type:
Grant
Filed:
September 3, 2021
Date of Patent:
January 16, 2024
Assignees:
IMMUNESENSOR THERAPEUTICS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Jian Qiu, Qi Wei, Matt Tschantz, Heping Shi, Youtong Wu, Hulling Tan, Lijun Sun, Chuo Chen, Zhijian Chen
Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
January 16, 2024
Assignee:
University of Tennessee Research Foundation
Inventors:
Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
Abstract: Novel 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds, a method of synthesizing these compounds, a pharmaceutical composition comprising these compounds and a suitable carrier, and a method of using the compounds. The 1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: Novel acridin-9-one derivative compounds having broad spectrum antibacterial activity, a method of making said compounds, methods of using said compounds, and a pharmaceutical composition comprising said compound(s) are provided. The acridin-9-one compounds have antimicrobial activity against various susceptible and resistant gram-positive and gram-negative bacteria as well as drug resistant bacteria. They act as DNA gyrase and topoisomerase IV inhibitors and are satisfiable as a drug for infectious treatment.
Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
Type:
Grant
Filed:
November 22, 2022
Date of Patent:
January 9, 2024
Assignee:
Incyte Corporation
Inventors:
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Abstract: The invention provides a compound of formula (Ia) or (Ib): or a salt thereof, wherein A, B, C, D, E, F, J, K, L, M, Q, V, X, Y, W and Z have any of the values described in the specification, as well as compositions comprising a compound of formula (Ia) or (Ib) or a salt thereof, and methods of use thereof.
Type:
Grant
Filed:
March 10, 2020
Date of Patent:
December 26, 2023
Assignee:
UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Christopher Pigge, Moustafa Tarek Ahmed Ibrahim Gabr
Abstract: Novel pyrido[4,3-b]indole-7-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[4,3-b]indole-7-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutical composition described herein.
Type:
Grant
Filed:
March 24, 2022
Date of Patent:
December 19, 2023
Inventors:
Donglei Liu, Julien Papillon, Stefan Peukert, James J. Powers
Abstract: Disclosed are syntheses of a Cot (cancer Osaka thyroid) inhibitor, which has the following formula:
Type:
Grant
Filed:
March 31, 2021
Date of Patent:
December 19, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Kevin M. Allan, Lina Chan, Andrei Chtchemelinine, Jeffrey T. Deignan, Kassibla E. Dempah, Kelly J. Eberle, Danielle M. Elfgren, Timothy G. Elford, Kevin D. Haggerty, Jesse W. Li, Tianmin Niu, Andrew C. Stevens, Ana F. Voica, Kevin S. Williamson, Boran Xu, Guojun Yu
Abstract: Provided herein are novel compounds, pharmaceutical compositions for use, inter alia, in methods of reducing Wnt-mediated effects and treating cancer.
Abstract: Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formula I.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
December 5, 2023
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE
Inventors:
Ana Maria Cuervo, Evripidis Gavathiotis
Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
Type:
Grant
Filed:
April 3, 2023
Date of Patent:
November 21, 2023
Assignee:
Flare Therapeutics Inc.
Inventors:
Jonathan E. Wilson, James E. Audia, Jacob I. Stuckey
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
Type:
Grant
Filed:
June 23, 2022
Date of Patent:
November 14, 2023
Assignees:
President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Type:
Grant
Filed:
June 13, 2022
Date of Patent:
October 24, 2023
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Christopher Lange, Viengkham Malathong, Darren J. McMurtrie, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
Abstract: Described herein are polymorphic forms of a CB1 modulator, methods of making such forms, pharmaceutical compositions and medicaments comprising such forms, and methods of using such forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of the CB1 receptor.
Type:
Grant
Filed:
October 10, 2022
Date of Patent:
October 24, 2023
Assignee:
ANEBULO PHARMACEUTICALS, INC.
Inventors:
Joseph Fenton Lawler, Daniel Pawel Schneeberger
Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK.
Type:
Grant
Filed:
July 15, 2021
Date of Patent:
October 17, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Philippe Fernandes, Paul J. Krawczuk, Mark S. Tichenor
Abstract: Vaccination is the most prevalent prophylactic means for controlling seasonal influenza infections. However, an effective vaccine usually takes at least 6 months to develop for the circulating strains. Therefore, new therapeutic options are needed for acute treatment of influenza infections to control this virus and prevent epidemic/pandemic situations from developing. Described herein are fast-acting, orally active acylated amino-substituted heterocyclyl compounds effective to control this virus. In one aspect, described herein is a method of treating an influenza infection in a subject comprising administering to the subject the compounds described herein.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
October 17, 2023
Assignees:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, CHICAGO BIOSOLUTIONS, INC.
Inventors:
Lijun Rong, Irina Gaisina, Gregory R. Thatcher, Norton Peet
Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.
Type:
Grant
Filed:
April 15, 2021
Date of Patent:
October 17, 2023
Assignee:
ESCIENT PHARMACEUTICALS, INC.
Inventors:
Marcos Sainz, Adam Yeager, Brandon Selfridge, Esther Martinborough, Marcus Boehm, Liming Huang